Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2022) 81 EP1129 | DOI: 10.1530/endoabs.81.EP1129

1ENT Department Farhat Hached Hospital Sousse, Sousse, Tunisia


The goal of this paper is to analyze the factors that cause people to flee medical treatment and to put forth management guidelines. Materials and methodes: This is a retrospective analysis of 27 instances with Graves’ disease that were resistive to medical treatment after escaping from well-conducted medical treatment in the ENT and cervico-facial surgery departments at Farhat Hached Sousse Hospital over a six-year period [2015-2021]. Results: All of the patients were put on a synthetic antithyroid medication as a first line of treatment (ATS). Carbimazole (thyrozol) was the most commonly used compound in 81.5 percent of instances, followed by propylthiouracil (basdene) in 18.5 percent. In 74 percent of instances, a beta-blocker was used as an adjuvant treatment. Medical treatment lasted an average of 33.7 months. Following an escape from medical treatment, surgical treatment was advised in all of the patients: resistance to medical treatment in 24 patients, 2 of whom had tried IRAtherapy cures but were ineffectual, and the presence of a gigantic goiter with compressive indicators in 3 patients. In all patients who achieved euthyroidism, a total thyroidectomy was performed (mean follow-up of 18 months).

Conclusion: Graves’ illness is the most prevalent cause of thyrotoxicosis, which has life-threatening effects. Iodine and surgery are the alternatives to euthyroidism, which must be achieved first.

Volume 81

European Congress of Endocrinology 2022

Milan, Italy
21 May 2022 - 24 May 2022

European Society of Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.

My recently viewed abstracts